Jardiance under the microscope: new study tracks heart failure outcomes in china
NCT ID NCT07047508
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will observe 3,000 adults in China with a type of heart failure called HFpEF who are starting the drug Jardiance. Researchers will track how many patients are hospitalized for heart failure or die from heart-related causes over time. The goal is to see how effective and safe the drug is in everyday medical practice, not in a controlled lab setting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?
- Can slow breathing soothe a failing heart?
- Can shedding pounds reboot the Heart's exercise engine?